BioCentury
ARTICLE | Finance

Itching to invest

VCs scratch out $50 million for Trevi based on data, strategic interest in pruritus

July 21, 2017 5:12 PM UTC

A growing strategic interest in pruritus underlies two series C rounds with multiple new investors that were announced the week of July 17. For Trevi Therapeutics Inc., the $50.5 million round announced July 20 is expected to be the company’s final private financing ahead of a takeout or IPO.

New investor New Enterprise Associates led the round and was joined by Aperture Venture Partners, Lundbeckfonden Ventures and Omega Funds, along with existing investor TPG Biotech...

BCIQ Company Profiles

Trevi Therapeutics Inc.